Ketamine is under clinical development by PharmaTher and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ketamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ketamine is under development for the treatment of status epilepticus, rett syndrome, amyotrophic lateral sclerosis (Lou Gehrig's disease), complex regional pain syndrome, depression, post-traumatic stress disorder, levodopa-induced dyskinesia in Parkinson's disease and ischemia-reperfusion injury from organ transplantation. It is administered through intravenous route. It is a psychedelic drug, which acts by targeting N-methyl-D-aspartate (NMDA) receptor. The drug candidate is being developed based on gelatin methacryloyl microneedle (GelMA-MN) delivery technology.
PharmaTher (PharmaThers) is a clinical-stage biotech company focused on the research, development, and commercialization of novel uses formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. It is headquartered in Toronto, Ontario, Canada.
For a complete picture of Ketamine’s drug-specific PTSR and LoA scores, buy the report here.